In the last trading session, 1.39 million shares of the Nektar Therapeutics (NASDAQ:NKTR) were traded, and its beta was 0.57. Most recently the company’s share price was $1.03, and it changed around -$0.04 or -3.74% from the last close, which brings the market valuation of the company to $173.75M. NKTR currently trades at a discount to its 52-week high of $1.93, offering almost -87.38% off that amount. The share price’s 52-week low was $0.42, which indicates that the current value has risen by an impressive 59.22% since then. We note from Nektar Therapeutics’s average daily trading volume that its 10-day average is 2.38 million shares, with the 3-month average coming to 1.26 million.
Nektar Therapeutics stock received a consensus recommendation rating of Buy, based on a mean score of 2.71. If we narrow it down even further, the data shows that 0 out of 14 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 3 recommended NKTR as a Hold, whereas 5 deemed it a Buy, and 1 rated it as Underweight. Nektar Therapeutics is expected to report earnings per share of -0.2 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Nektar Therapeutics (NASDAQ:NKTR) trade information
Instantly NKTR has showed a red trend with a performance of -3.74% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.3750 on recent trading dayincreased the stock’s daily price by 25.09%. The company’s shares are currently up 82.30% year-to-date, but still down -24.82% over the last five days. On the other hand, Nektar Therapeutics (NASDAQ:NKTR) is -26.95% down in the 30-day period. We can see from the shorts that 5.23 million shares have been sold at a short interest cover period of 3.91 day(s).
The consensus price target as assigned by Wall Street analysts is $18.5, which translates to bulls needing to increase their stock price by 94.43% from its current value. Analyst projections state that NKTR is forecast to be at a low of $6 and a high of $24.
Nektar Therapeutics (NKTR) estimates and forecasts
Nektar Therapeutics share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -41.14 percent over the past six months and at a 47.59% annual growth rate that is well above the industry average of 15.60%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 10.36% in revenue this quarter, and will report a decrease of -19.57% in the next quarter. The year-over-year growth rate is expected to be 8.90%, up from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 29.91M in revenue for the current quarter. 3 analysts expect Nektar Therapeutics to make 24.03M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 23.89M and 21.64M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 25.21%. Forecasts for the next quarter put sales growth at 11.06%.
Nektar Therapeutics earnings are expected to increase by 49.00% in 2024, but the outlook is negative -7.30% per year for the next five years.
NKTR Dividends
Nektar Therapeutics’s next quarterly earnings report is expected to be released in December.
Nektar Therapeutics (NASDAQ:NKTR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.05% of Nektar Therapeutics shares, and 76.69% of them are in the hands of institutional investors. The stock currently has a share float of 77.50%. Nektar Therapeutics stock is held by 177.0 institutions, with DEEP TRACK CAPITAL, LP being the largest institutional investor. By 2024-06-30, it held 9.1789% of the shares, which is about 17.88 million shares worth $22.17 million.
BLACKROCK INC., with 7.7823% or 15.16 million shares worth $18.79 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
